Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alpha Cognition Inc C.ACOG

Alternate Symbol(s):  ACOGF

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

Recent & Breaking News (CSE:ACOG)

Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Business Wire April 3, 2024

Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.

Business Wire March 20, 2024

Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer's Disease

Business Wire February 22, 2024

Alpha Cognition Provides Business Update

Business Wire February 12, 2024

Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment

Business Wire January 19, 2024

Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering

Business Wire December 22, 2023

FDA approves Alpha Cognition’s new drug application for Alzheimer’s

Jonathon Brown December 8, 2023

Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease

Business Wire December 7, 2023

Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering

Business Wire December 4, 2023

Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update

Business Wire November 28, 2023

Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering

Business Wire November 8, 2023

Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering

Business Wire October 16, 2023

Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease

Business Wire September 27, 2023

Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering

Business Wire August 31, 2023

Alpha Cognition Announces Second Quarter and Six Months Ended 2023 Results and Provides Corporate Update

Business Wire August 22, 2023

Alpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer's Disease

Business Wire August 14, 2023

Canadian Securities Exchange Reports May 2023 Performance Figures

Newsfile June 20, 2023

Health care stock receives Army grant for traumatic brain injury study

Jonathon Brown June 7, 2023

Alpha Cognition Receives Army Medical Research Grant for Study on Mild Traumatic Brain Injury (mTBI) from Blast Induced Functional Deficit and Brain Pathology

Business Wire June 7, 2023

Alpha Cognition Announces First Quarter 2023 Results and Provides Corporate Update

Business Wire May 30, 2023